Skip to main content

Advertisement

Fig. 3 | BMC Ophthalmology

Fig. 3

From: Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

Fig. 3

(Supplementary) Improvement in BCVA and reduction in retinal thickness at 1, 2 and 3 years after treatment with FAc implant in those patients who did not require supplementary treatment. Graph (a) showing mean values for ETDRS letters gained, mean (SD) central retinal thickness (CRT) and peak macular thickness as measured by SD-OCT. Significance at each time-point was tested against baseline (b)

Back to article page